Waiting for the national cholesterol education program adult treatment panel IV guidelines, and in the meantime, some challenges and recommendations

American Journal of Cardiology

Volumn 110, Issue 2, 2012, Pages 307-313

  Martin, Seth S ^a   Metkus, Thomas S ^a   Horne, Aaron ^a   Blaha, Michael J ^a   Hasan, Rani ^a   Campbell, Catherine Y ^a   Yousuf, Omair ^a   Joshi, Parag ^a   Kaul, Sanjay ^b   Miller, Michael ^c   Michos, Erin D ^a   Jones, Steven R ^a   Gluckman, Ty J ^d   Cannon, Christopher P ^e   Sperling, Laurence S ^f   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Providence Heart and Vascular Institute   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACCURACY; ALGORITHM; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; DIABETES MELLITUS; EDUCATION PROGRAM; EXERCISE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; RISK ASSESSMENT; TREATMENT PLANNING;

ADULT; ALGORITHMS; APOLIPOPROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TERMINOLOGY AS TOPIC; UNITED STATES;

EID: 84862758583     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.03.023     Document Type: Conference Paper

References (30)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr, N.J. Stone Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines J Am Coll Cardiol 44 2004 720 732
3. D.M. Lloyd-Jones, E.P. Leip, M.G. Larson, R.B. D'Agostino, A. Beiser, P.W. Wilson, P.A. Wolf, D. Levy Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 113 2006 791 798
4. A.S. Go, C. Iribarren, M. Chandra, P.V. Lathon, S.P. Fortmann, T. Quertermous, M.A. Hlatky Statin and beta-blocker therapy and the initial presentation of coronary heart disease Ann Intern Med 144 2006 229 238
5. J.S. Berger, C.O. Jordan, D. Lloyd-Jones, R.S. Blumenthal Screening for cardiovascular risk in asymptomatic patients J Am Coll Cardiol 55 2010 1169 1177
6. P. Greenland, J.S. Alpert, G.A. Beller, E.J. Benjamin, M.J. Budoff, Z.A. Fayad, E. Foster, M.A. Hlatky, J.M. Hodgson, F.G. Kushner, M.S. Lauer, L.J. Shaw, S.C. Smith Jr, A.J. Taylor, W.S. Weintraub, N.K. Wenger, A.K. Jacobs, J.L. Anderson, N. Albert, C.E. Buller, M.A. Creager, S.M. Ettinger, R.A. Guyton, J.L. Halperin, J.S. Hochman, R. Nishimura, E.M. Ohman, R.L. Page, W.G. Stevenson, L.G. Tarkington, C.W. Yancy 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2010 e50 e103
7. M.J. Blaha, M.J. Budoff, A.P. DeFilippis, R. Blankstein, J.J. Rivera, A. Agatston, D.H. O'Leary, J. Lima, R.S. Blumenthal, K. Nasir Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study Lancet 378 2011 684 692
8. A.L. Catapano, Z. Reiner, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, D. Wood ESC/EAS guidelines for the management of dyslipidaemias the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
9. C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
10. D.M. Lloyd-Jones, Y. Hong, D. Labarthe, D. Mozaffarian, L.J. Appel, L. Van Horn, K. Greenlund, S. Daniels, G. Nichol, G.F. Tomaselli, D.K. Arnett, G.C. Fonarow, P.M. Ho, M.S. Lauer, F.A. Masoudi, R.M. Robertson, V. Roger, L.H. Schwamm, P. Sorlie, C.W. Yancy, W.D. Rosamond Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond Circulation 121 2010 586 613
11. R.A. Hayward, H.M. Krumholz Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health Circ Cardiovasc Qual Outcomes 5 2012 2 5
12. G.B. Mancini, S. Baker, J. Bergeron, D. Fitchett, J. Frohlich, J. Genest, M. Gupta, R.A. Hegele, D. Ng, J. Pope Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 2011 635 662
13. B. Mihaylova, A. Briggs, J. Armitage, S. Parish, A. Gray, R. Collins Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people BMJ 333 2006 1 5
14. F.G. Kushner, M. Hand, S.C. Smith Jr, S.B. King III, J.L. Anderson, E.M. Antman, S.R. Bailey, E.R. Bates, J.C. Blankenship, D.E. Casey Jr, L.A. Green, J.S. Hochman, A.K. Jacobs, H.M. Krumholz, D.A. Morrison, J.P. Ornato, D.L. Pearle, E.D. Peterson, M.A. Sloan, P.L. Whitlow, D.O. Williams 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
15. R.S. Wright, J.L. Anderson, C.D. Adams, C.R. Bridges, D.E. Casey Jr, S.M. Ettinger, F.M. Fesmire, T.G. Ganiats, H. Jneid, A.M. Lincoff, E.D. Peterson, G.J. Philippides, P. Theroux, N.K. Wenger, J.P. Zidar, E.M. Antman, R.M. Califf, W.E. Chavey II, J.S. Hochman, T.N. Levin 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons J Am Coll Cardiol 57 2011 e215 e367
16. J. Genest, R. McPherson, J. Frohlich, T. Anderson, N. Campbell, A. Carpentier, P. Couture, R. Dufour, G. Fodor, G.A. Francis, S. Grover, M. Gupta, R.A. Hegele, D.C. Lau, L. Leiter, G.F. Lewis, E. Lonn, G.B. Mancini, D. Ng, G.J. Pearson, A. Sniderman, J.A. Stone, E. Ur 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
17. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, I. Ford Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
18. G.O. Coodley, M. Jorgensen, J. Kirschenbaum, C. Sparks, L. Zeigler, B.D. Albertson Lowering LDL cholesterol in adults: a prospective, community-based practice initiative Am J Med 121 2008 604 610
19. J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, J.H. Stein, J.L. Witztum Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
20. I. Tabas, K.J. Williams, J. Boren Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844
21. A.D. Sniderman, K. Williams, J.H. Contois, H.M. Monroe, M.J. McQueen, J. de Graaf, C.D. Furberg A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
22. P.J. Barter, C.M. Ballantyne, R. Carmena, M. Castro Cabezas, M.J. Chapman, P. Couture, J. de Graaf, P.N. Durrington, O. Faergeman, J. Frohlich, C.D. Furberg, C. Gagne, S.M. Haffner, S.E. Humphries, I. Jungner, R.M. Krauss, P. Kwiterovich, S. Marcovina, C.J. Packard, T.A. Pearson, K.S. Reddy, R. Rosenson, N. Sarrafzadegan, A.D. Sniderman, A.F. Stalenhoef, E. Stein, P.J. Talmud, A.M. Tonkin, G. Walldius, K.M. Williams Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Intern Med 259 2006 247 258
23. H. Scharnagl, M. Nauck, H. Wieland, W. Marz The Friedewald formula underestimates LDL cholesterol at low concentrations Clin Chem Lab Med 39 2001 426 431
24. M.H. Davidson, C.M. Ballantyne, T.A. Jacobson, V.A. Bittner, L.T. Braun, A.S. Brown, W.V. Brown, W.C. Cromwell, R.B. Goldberg, J.M. McKenney, A.T. Remaley, A.D. Sniderman, P.P. Toth, S. Tsimikas, P.E. Ziajka, K.C. Maki, M.R. Dicklin Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367
25. V. Ramjee, L.S. Sperling, T.A. Jacobson Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math J Am Coll Cardiol 58 2011 457 463
26. Centers for Disease Control and Prevention NHANES 2007 - 2008: laboratory files http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/lab07-08.htm Accessed December 21, 2011
27. J.H. O'Keefe Jr, L. Cordain, W.H. Harris, R.M. Moe, R. Vogel Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal J Am Coll Cardiol 43 2004 2142 2146
28. P. Parikh, M.C. McDaniel, M.D. Ashen, J.I. Miller, M. Sorrentino, V. Chan, R.S. Blumenthal, L.S. Sperling Diets and cardiovascular disease: an evidence-based assessment J Am Coll Cardiol 45 2005 1379 1387
29. D.M. Bravata, C. Smith-Spangler, V. Sundaram, A.L. Gienger, N. Lin, R. Lewis, C.D. Stave, I. Olkin, J.R. Sirard Using pedometers to increase physical activity and improve health: a systematic review JAMA 298 2007 2296 2304
30. T.J. Gluckman, B. Baranowski, M.D. Ashen, C.A. Henrikson, M. McAllister, J.B. Braunstein, R.S. Blumenthal A practical and evidence-based approach to cardiovascular disease risk reduction Arch Intern Med 164 2004 1490 1500